Navigation Links
Study links microRNA to shut-down of DNA-repair genes

COLUMBUS, Ohio New research shows for the first time that molecules called microRNA can silence genes that protect the genome from cancer-causing mutations.

The study, led by researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, shows that microRNA-155 (miR-155) can inhibit the activity of genes that normally correct the damage when the wrong bases are paired in DNA.

The loss or silencing of these genes, which are called mismatch repair genes, causes inherited cancer-susceptibility syndromes and contributes to the progression of colorectal, uterine, ovarian and other cancers.

"This is the first evidence that deregulation of microRNAs can cause genomic instability, a characteristic of cancer cells," says principal investigator Dr. Carlo M. Croce, professor of Molecular Virology, Immunology and Medical Genetics, and director of Ohio State's Human Cancer Genetics program.

"We discovered that miR-155 targets and downregulates mismatch repair genes and that overexpression of miR-155 results in an increase in genomic alterations that contribute to cancer pathogenesis," he says.

The study was published recently in the Proceedings of the National Academy of Sciences and shows the following:

  • Overexpression of miR-155 reduced the expression of the human mismatch repair genes MLH1, MSH2 and MSH6 by 72 percent, 42 percent and 69 percent, respectively, in a colorectal cancer cell line.
  • High expression of miR-155 in human colorectal tumors correlates with low expression of MLH1 and MSH2.
  • Human tumors that feature unexplained mismatch repair inactivation showed miR-155 overexpression.

The third finding may explain a colon-cancer conundrum. About five percent of colorectal cancer cases feature a genomic marker called microsatellite instability that signals the loss of mismatch repair ability and the presence of an inherited cancer predisposition condition. These cases also show no expression of mismatch genes. Yet, the genes themselves show no alterations that explain the loss of expression.

"This study describes a totally new mechanism that might explain those cases of colorectal cancer that display microsatellite instability but no mutations or epigenetic inactivation of the mismatch repair genes," says co-author Muller Fabbri, a research scientist with the OSUCCC-James.

Overall, Croce says, "Our findings suggest that miR-155 expression might be an important stratification factor in the prognosis and treatment of cancer patients and provide an additional analytical test for exploring the etiology of microsatellite-instability tumors when the standard tests do not provide a conclusive diagnosis."


Contact: Darrell E. Ward
Ohio State University Medical Center

Related medicine news :

1. Study: Carbon Monoxide Exposure Can be Reduced During Routine Anesthesia in Kids
2. UGA, Emory to study how exercise may prevent drug abuse relapse
3. Racial disparity observed in varus and valgus thrust study of knee OA
4. U-M study: Use of alternative therapy for pain treatment increases with age and wealth
5. NIH study offers hope to patients with nonalcoholic steatohepatitis
6. Twins Study Points to Environmental Cause for MS
7. Fibromyalgia affects mental health of those diagnosed and their spouses, study finds
8. Children's Rights Group Agrees with New Study: Infant Circumcision Causes 100 Deaths Each Year in US
9. Cell study finds receptor can fight tamoxifen-resistant breast cancer cells
10. Study examines global availability of treatment involving transplantation of blood stem cells
11. Study finds that drugs used for treatment of influenza in pregnancy appear to be safe
Post Your Comments:
(Date:11/30/2015)... DC (PRWEB) , ... November ... ... Inc. (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: ... lessons learned from three innovative value-based care arrangements: Essentia Health and UCare, ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in the ... Matrix is a long-term resorbable surgical mesh intended to support and reinforce soft ...
(Date:11/30/2015)... Puerto Rico (PRWEB) , ... November 30, 2015 , ... ... active part of the San Juan Beauty Show held on November 8th and 9th ... was attended by media personalities, hair artists, renowned beauticians and top of the line ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... are pleased to announce their strategic partnership at the Radiological Society of ... Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation ...
(Date:11/30/2015)... ... 30, 2015 , ... World Patent Marketing , a ... household invention that provides an economical and easy way of gaining customized curtains. ... at 2.6%," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015   VolitionRx Limited (NYSE MKT: ... tests for a broad range of cancer types and other ... Micro Conference, which will be held December 1 - 3 in ... VolitionRx will be David Kratochvil , Chief Financial Officer ... Investor Relations. ® blood-based tests for colorectal ...
(Date:11/30/2015)... , November 30, 2015 PFE ... at up to 10 G protein-coupled receptor (GPCR) targets ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> Heptares Therapeutics ("Heptares"), ... and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE ...
(Date:11/30/2015)... and REHOVOT, Israel , ... specialty pharmaceutical company focused on acquiring and developing innovative ... announced the appointment of Keith A. Katkin ... Gregory J. Flesher , chief executive officer for ... building successful organizations.  As chairman, he will be able ...
Breaking Medicine Technology: